The In Vitro Effects of a Novel Vascular Protectant,AGI-1067,on Platelet Aggregation and Major Receptor Expression in Subjects With Multiple Risk Factors for Vascular Disease
Free accessResearch articleFirst published online September, 2006
The In Vitro Effects of a Novel Vascular Protectant,AGI-1067,on Platelet Aggregation and Major Receptor Expression in Subjects With Multiple Risk Factors for Vascular Disease
Oxidation-sensitive signals are important in platelet activation. The novel, phenolic, intracellular and extra-cellular antioxidant AGI-1067 inhibits the expression of a number of proinflammatory genes involved in atherosclerosis. The effect of AGI-1067 on human platelets was evaluated. Blood obtained from 20 aspirin-naïve volunteers with multiple risk factors for vascular disease was preincubated with escalating concentrations of AGI-1067 for the assessment of its ex vivo effects on platelet aggregation and expression of major surface receptors flow cytometry, evaluated by flow cytometry. AGI-1067 resulted in significant inhibition of a variety of activation-dependent platelet biomarkers in healthy volunteers, including adenosine diphosphate-induced platelet aggregation and decreased surface platelet expression of glycoprotein IIb/IIIa antigen, activity with PAC-1 antibody, and glycoprotein Ib (CD42b). The effect of AGI-1067 differs from other known antiplatelet agents, suggesting opportunities for therapeutic combination. These data need to be confirmed in subjects receiving orally dosed AGI-1067 to be clinically relevant.
Libby P.Changing concepts of atherogenesis. J Intern Med. 2000;247: 349-358.
2.
Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL.Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320: 915-924.
3.
Salonen JT, Yla-Herttuala S, Yamamoto R, et al.Auto-antibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 1992;339: 883-887.
4.
Rodes J, Cote G, Lesperance J, et al.Prevention of restenosis after angioplasty in small coronary arteries with probucol. Circulation. 1998;97: 429-436.
5.
Cote G, Tardif JC, Lesperance J, et al.Effects of probucol on vascular remodeling after coronary angioplasty. Multivitamins and Protocol Study Group. Circulation. 1999;99: 30-35.
6.
Sundell CL, Somers PK, Meng CQ, et al.AGI-1067: a multifunctional phenolic antioxidant, lipid modulator, anti-inflammatory and antiatherosclerotic agent. J Pharmacol Exp Ther. 2003;305: 1116-1123.
7.
Ruggeri ZM.New insights into the mechanisms of platelet adhesion and aggregation. Semin Hematol. 1994; 31: 229-239.
8.
Ault KA.Flow cytometric measurement of platelet function and reticulated platelets. Ann New York Acad Sci. 1993;677: 293-308.
9.
Serebruany VL, Gurbel PA.The relations of major platelet receptor expression during myocardial infarction. Monitoring efficacy of GPIIb/IIIa inhibitors by measuring P-selectin?Thromb Haemost. 1999;81: 314-316.
10.
Serebruany VL, Gurbel PA, O’Connor CM.Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharm Res. 2001;43: 453-462.
11.
Serebruany VL, Malinin AI, Lowry DR, et al.Platelet inhibition by valsartan and valeryl 4-hydroxy valsartan: a possible missing link to explain benefits of angiotensin ii receptor blockers in patients after acute vascular events. J Cardiovasc Pharm.2004;43: 677-684.
12.
Serebruany VL, Ordonez JV, Herzog WR, et al.Dietary coenzyme Q10 supplementation alters platelet size and inhibits human vitronectin (CD51/CD61) receptor expression. J Cardiovasc Pharm. 1997;29: 16-22.
13.
Kunsch C, Medford RM.Oxidative stress as a regulator of gene expression in the vasculature. Circ Res. 1999; 85: 753-766.
14.
Li H, Cybulsky MI, Gimbrone MA Jr, Libby P.An atherogenic diet rapidly induces VCAM-1, a cytokineregulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb. 1993; 13: 197-204.
15.
Gerszten RE, Lim Y, Ding HT, et al.Adhesion of monocytes to vascular cell adhesion molecule-1-transduced human endothelial cells: implications for atherogenesis. Circ Res. 1998;82: 871-878.
16.
Rohde LE, Lee RT, Rivero J, et al.Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arterioscler Thromb Vasc Biol. 1998;18: 1765-1770.
17.
Blankenberg S, Rupprecht HJ, Bickel C, et al.Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation. 2001;104: 1336-1342.
18.
Narizhneva NV, Razorenova OV, Podrez EA, et al.Thrombospondin-1 up-regulates expression of cell adhesion molecules and promotes monocyte binding to endothelium. FASEB J. 2005;19: 1158-1160.
19.
van der Zijpp YJ, Poot AA, Feijen J.ICAM-1 and VCAM-1 expression by endothelial cells grown on fibronectin-coated TCPS and PS. J Biomed Mater Res A. 2003;65: 51-59.
20.
Gawaz M, Page S, Massberg S, et al.Transient platelet interaction induces MCP-1 production by endothelial cells via I kappa B kinase complex activation. Thromb Haemost. 2002;88: 307-314.
21.
Mayer K, Merfels M, Muhly-Reinholz M, et al.Omega- 3 fatty acids suppress monocyte adhesion to human endothelial cells: role of endothelial PAF generation. Am J Physiol Heart Circ Physiol. 2002;283: H811-H818.
22.
Rinder HM, Bonan JL, Rinder CS, Ault KA, Smith BR.Dynamics of leukocyte-platelet adhesion in whole blood. Blood. 1991;78: 1730-1737.
23.
Weyrich AS, Elstad MR, McEver RP, et al.Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest. 1996;97: 1525-1534.
24.
Selley ML, Bartlett MR, Czeti AL, Ardlie NG.The role of (E)-4-hydroxy-2-nonenal in platelet activation by low-density lipoprotein and iron. Atherosclerosis. 1998;140: 105-112.
25.
Simons LA, Balasubramaniam S, Beins DM.Metabolic studies with probucol in hypercholesterolaemia. Atherosclerosis. 1981;40: 299-308.
26.
Nomura S, Takahashi N, Inami N, et al.Probucol and ticlopidine: effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetes. Atherosclerosis. 2004;174: 329-335.
